Free Trial

Vertex Pharmaceuticals (VRTX) Earnings Date, Estimates & Call Transcripts

Vertex Pharmaceuticals logo
$451.23 +3.22 (+0.72%)
(As of 11/20/2024 ET)

Vertex Pharmaceuticals Latest Earnings Summary

Upcoming Q4
Earnings Date
Feb. 3Estimated
Actual EPS
(Nov. 4)
$4.38 Beat By $0.77
Consensus EPS
(Nov. 4)
$3.61

Vertex Pharmaceuticals issued Q3 2024 earnings on November 4, 2024, reporting an EPS of $4.38, which beat the consensus estimate of $3.61 by $0.77. Quarterly revenue rose 11.6% year-over-year to $2.77 billion, above analysts' expectations of $2.69 billion. With a trailing EPS of -$1.99, Vertex Pharmaceuticals' earnings are expected to grow next year, from ($1.82) to $16.25 per share.

VRTX Upcoming Earnings

Vertex Pharmaceuticals' next earnings date is estimated for Monday, February 3, 2025, based off prior year's reporting schedules.

Get Vertex Pharmaceuticals Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vertex Pharmaceuticals and other key companies, straight to your inbox.

Sign Up
Skip Charts & View Estimated and Actual Earnings Data

VRTX Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

VRTX Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Vertex Pharmaceuticals Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20242$3.56$3.73$3.65
Q2 20243-$13.85$3.81-$2.16
Q3 20243$3.56$3.68$3.62
Q4 20243$3.60$4.08$3.78
FY 202411-$3.13$15.30$8.90
Q1 20251$3.85$3.85$3.85
Q2 20251$4.09$4.09$4.09
Q3 20251$3.97$3.97$3.97
Q4 20251$4.01$4.01$4.01
FY 20254$15.92$15.92$15.92
Q1 20261$4.08$4.08$4.08
Q2 20261$4.23$4.23$4.23
Q3 20261$4.44$4.44$4.44

Vertex Pharmaceuticals Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks
2/3/2025
(Estimated)
------- 
11/4/2024Q3 2024$3.61$4.38+$0.77$4.07$2.69B$2.77B          
8/1/2024Q2 2024-$12.54-$12.83 -$0.29-$12.62$2.66B$2.65B        
5/6/2024Q1 2024$3.66$4.76+$1.10$4.37$2.58B$2.69B        
2/5/2024Q4 2023$3.85$4.20+$0.35$3.43$2.50B$2.52B        
11/6/2023Q3 2023$3.53$4.08+$0.55$3.37$2.50B$2.48B          
8/1/2023Q2 2023$3.47$3.53+$0.06$3.54$2.41B$2.49B    
5/1/2023Q1 2023$2.51$3.05+$0.54$2.65$2.34B$2.37B        
2/7/2023Q4 2022$3.11$3.76+$0.65$3.51$2.30B$2.30B        

Vertex Pharmaceuticals Earnings - Frequently Asked Questions

Vertex Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, February 3rd, 2025 based off last year's report dates. Learn more on VRTX's earnings history.

Vertex Pharmaceuticals issued an update on its FY 2024 earnings guidance on Monday, November, 4th. The company issued revenue guidance of $10.8 billion-$10.9 billion, compared to the consensus revenue estimate of $10.8 billion.

In the previous quarter, Vertex Pharmaceuticals (NASDAQ:VRTX) reported $4.38 earnings per share (EPS) to beat the analysts' consensus estimate of $3.61 by $0.77. Learn more on analysts' earnings estimate vs. VRTX's actual earnings.

The conference call for Vertex Pharmaceuticals's latest earnings report can be listened to online.
Listen to Conference Call

The conference call transcript for Vertex Pharmaceuticals's latest earnings report can be read online.
Read Transcript

Vertex Pharmaceuticals's earnings report can be found in their filing with the SEC.
View SEC filing

Vertex Pharmaceuticals (NASDAQ:VRTX) has a recorded annual revenue of $9.87 billion.

Vertex Pharmaceuticals (NASDAQ:VRTX) has a recorded net income of $3.62 billion. VRTX has generated -$1.99 earnings per share over the last four quarters.

Vertex Pharmaceuticals's earnings are expected to grow from ($1.82) per share to $16.25 per share in the next year.

`

More Earnings Resources from MarketBeat



This page (NASDAQ:VRTX) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners